KRAS and intraepithelial neoplasia: Constitutively activated KRAS subsequently upregulates the endogenous expression of the upstream protein epidermal growth factor receptor (EGFR) and induces its hyperactivation [29, 30], and increased RAS levels and EGFR activity induce robust increases MEK/ERK activity, leading to intraepithelial neoplasia [31].